Compare Albertsons Companies Inc (ACI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs IDEXX Laboratories, Inc. — how do they compare? Albertsons Companies Inc trades at $12.03 (market cap $5.95B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.8× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays a 5.55% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ACI | IDXX | |
|---|---|---|
Market Cap | $5.95B | $46.22B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $766.68 |
52-Week Low | $11.03 | $526.44 |
Enterprise Value | $21.35B | $47.12B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $11.98, down 1.24% with bearish technical signals despite recent insider buying by the CEO and CFO. The stock shows mixed fundamentals with strong revenue growth to $80.39B in 2025 but declining net margins to 0.08%. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple legal investigations. Analyst consensus remains cautious with a $13.20 price target and 56.52% hold rating.
ACI presents a high-risk opportunity trading near multi-year lows with potential upside to analyst targets. Key catalysts include ACI Edge restructuring and digital initiatives, but investors face significant execution risks amid margin pressure and competitive grocery markets. The stock's deep value case is complicated by earnings volatility and ongoing legal scrutiny.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
